PD-1 and PD-L1 in Cancer Immunotherapy

Dear Colleagues,

The PD-1/PD-L1 axis has emerged as a critical pathway in cancer immunotherapy, revolutionizing the treatment landscape for numerous malignancies. Immune checkpoint inhibitors targeting PD-1 and PD-L1 have demonstrated remarkable clinical efficacy across a wide range of tumor types. However, significant challenges remain, including understanding the mechanisms of resistance, identifying predictive biomarkers, and optimizing combination therapies to enhance therapeutic outcomes.

This Special Issue aims to highlight cutting-edge research and advancements in the field of PD-1/PD-L1 immunotherapy. We welcome original research articles and reviews that explore the molecular mechanisms of PD-1/PD-L1 signaling, the development of novel therapeutic strategies, and the integration of single-cell and spatial omics technologies to unravel the complexities of tumor–immune interactions. Contributions addressing the clinical challenges of resistance, toxicity management, and patient stratification are also encouraged.

We look forward to receiving your contributions.

Dr. Aleksandar Obradovic
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.